



## Product Data Sheet

---

<b>Product Name:</b>	TAT (47-57)	
<b>Catalog Number:</b>	AS-60023-1 (1 mg) AS-60023-5 (5 mg)	Lot Number: See label on vial
<b>Sequence:</b>	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-OH (3-letter code) YGRKKRRQRRR (1-letter code)	
<b>Molecular Weight:</b>	1559.9	
<b>Peptide Purity:</b>	>95%	
<b>Appearance:</b>	Lyophilized white powder	

**Peptide Reconstitution:** TAT (47-57) peptide is freely soluble in water.

**Storage:** TAT (47-57) peptide is shipped at ambient temperature. Upon receipt, store lyophilized peptide at  $-20^{\circ}\text{C}$  or lower. Reconstituted peptide can be aliquoted and stored at  $-20^{\circ}\text{C}$  or lower.

**Description:** This is the most characterized fragment of the HIV transactivator protein (TAT). This arginine-rich TAT peptide penetrates plasma membrane directly, but not through endocytosis. Ref: Wang, H. et al. *J. Clin. Invest.* **109**, 1463 (2002); Ziegler et al. *Biochem.* **44**, 138 (2005); Wender, PA. et al. *Proc. Natl. Acad. Sci. USA* **97**, 13003 (2000).

**Additional Information:** Listed below are relevant information that may provide a guideline on how to use this product. End users will have to adapt to their own specific applications.

All the animal studies were done in accordance with protocol no. 00-084-09 obtained from Institutional Animal Care and Use Committee. For biodistribution studies,  $4 \times 10^6$  LS174T cells, a human colon carcinoma cell line, were implanted s.c. in female athymic mice (*nu/nu*; 4-6 weeks old; Charles River, Wilmington, MA). The mice were used 10 to 14 days following implantation (tumor volume,  $\approx 200\text{-}300 \text{ mm}^3$ ). Biodistribution studies were done after an injection of  $[^{125}\text{I}]\text{sc}(\text{Fv})_2$  (5  $\mu\text{Ci}/\text{animal}$ ) via the tail vein either alone or in conjunction with 200  $\mu\text{L}$  of 12.5  $\mu\text{mol}/\text{L}$  penetratin (RQIKIWFQNRRMKWKK) or TAT (YGRKKRRQRR) peptides (Anaspec, San Jose, CA)- [Jain, M. et al. \*Cancer Res.\* \*\*65\*\*, 7840 \(2005\).](#)

### Published Citations:

Jain, M. et al. *Cancer Res.* **65**, 7840 (2005).  
Matsushita, K. et al. *Mol. Pharmacol.* **67**, 1137 (2005).

### Related Products:

Name	Cat #	Size
FITC-LC-TAT (47-57)	AS-27042	0.5 mg
FITC-LC-YGRKKRRQRRR-NH2	AS-27043	1 mg

TAT (47-57), TAMRA-labeled TAMRA-YGRKKRRQRRR	AS-61211	1 mg
TAT (47-57), FAM-labeled FAM-YGRKKRRQRRR	AS-61210	1 mg
TAT (47-57) GGG-Cys(Npys) YGRKKRRQRRRGGG-C(Npys)-NH2	AS-61215	1 mg
Cys(Npys)-TAT (47-57), FAM-labeled C(Npys)YGRKKRRQRRR-K(FAM)-NH2	AS-61213	1 mg
Cys(Npys)-TAT (47-57) C(Npys)YGRKKRRQRRR-NH2	AS-61214	1 mg
Biotin-TAT (47-57) Biotin-YGRKKRRQRRR	AS-61209	1 mg
Cys-TAT (47-57) CYGRKKRRQRRR-NH2	AS-61212	1 mg

*For Research Use Only*